Can CDK 4/6 inhibitors be used in patients with visceral crises? Deviating from conventional teaching
Open Access
- 12 April 2022
- journal article
- Published by Scientific Scholar in International Journal of Molecular and Immuno Oncology
- Vol. 7, 33-35
- https://doi.org/10.25259/ijmio_8_2022
Abstract
Visceral crisis is a situation in which the vital organ function is impaired due to infiltration by cancer cells. It Is of particular importance in the subset of HR+/Her2- metastatic breast cancer.. Current guidelines that recommend cytotoxic chemotherapy for visceral crisis are based on historical data that indicate that chemotherapy has higher response rates than endocrine therapy. These trials included patients with advanced breast cancer who were not selected for the hormonal receptor or Her 2 receptor status. In addition, the comparator had a weak endocrine agent. Objective response rates with endocrine therapy in combination with any of the CDK 4/6 inhibitors in patients with measurable disease range from 50-59%. These response rates are higher than the chemotherapy rates found in the historical trials. Moreover, patients with visceral crisis have a compromised performance status and impaired organ functions. Therefore, it is unlikely that these patients would tolerate complete doses of the most active chemotherapeutic agents, including anthracycline and taxane. The retrospective analysis of the real-world data base clearly demonstrates that the combination of endocrine agents with a CDK 4/6 inhibitor is superior to chemotherapy with improvement in overall survival. In conclusion, it is time to redefine the guidelines and consider endocrine therapy with a CDK 4/6 combination as the preferred option in the initial management of the visceral crisis.Keywords
This publication has 9 references indexed in Scilit:
- Efficacy of CDK4/6i in the visceral crisis setting: Result from a real-world database.Journal of Clinical Oncology, 2021
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)Annals of Oncology, 2020
- Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trialBreast Cancer Research and Treatment, 2017
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast CancerJournal of Clinical Oncology, 2017
- Visceral Crisis Means Short Survival Among Patients With Luminal A Metastatic Breast Cancer: A Retrospective Cohort StudyWorld Journal of Oncology, 2017
- A Review of Systemic Treatment in Metastatic Triple-Negative Breast CancerBreast Cancer: Basic and Clinical Research, 2016
- What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?Annals of Oncology, 2009
- Combination Chemotherapy Compared to Tamoxifen as Initial Therapy for Stage IV Breast Cancer in Elderly WomenAnnals of Internal Medicine, 1986
- A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia.Journal of Clinical Oncology, 1986